- $53.70m
- $44.23m
- $1.12m
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer
RenovoRx Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
Brief: Renovorx Announces $10 Million At Market Private Placement
Brief: Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
Brief: RenovoRx May Offer Securities For Up To $50 Million - SEC Filing
Cancer drug developer RenovoRx's Q3 net loss widens
Brief: RenovoRx Q3 Net Income USD -2.912 Million
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary